A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~75 mi. (México, Mexico, +202 more cities)

Site MX52002

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~75 mi. (México, Mexico, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

~75 mi. (México, Mexico, +135 more cities)

Cryptex Investigacion Clinica SA de CV

PD-L1 Expression (IC >= 10%), +1 more biomarker

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.

~75 mi. (México, Mexico, +137 more cities)

Local Institution

Bladder Urothelial Carcinoma

bempegaldesleukin, +2 more drugs

immunotherapy, +2 more types

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

~75 mi. (México, Mexico, +50 more cities)

COI Centro Oncológico Internacional S.A.P.I. de C.V.

Cervical Adenocarcinoma, +2 more conditions

balstilimab, +2 more drugs

immunotherapy

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~94 mi. (Santiago de Querétaro, Mexico, +144 more cities)

Cuidados Oncologicos ( Site 0608)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~94 mi. (Santiago de Querétaro, Mexico, +105 more cities)

Cuidados Oncologicos ( Site 2908)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

~94 mi. (Santiago de Querétaro, Mexico, +34 more cities)

Cuidados Oncologicos

Clear Cell Renal Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~94 mi. (Santiago de Querétaro, Mexico, +115 more cities)

Cuidados Oncologicos ( Site 3104)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

~98 mi. (Cuauhtémoc, Mexico, +163 more cities)

Investigational Site Number :4840003

CEACAM5 Expression

Non-Squamous Non-Small Cell Lung Carcinoma

tusamitamab ravtansine

chemotherapy, +1 more type

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~99 mi. (Mexico City, Mexico, +192 more cities)

Grupo Medico Camino Sc

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~99 mi. (Mexico City, Mexico, +247 more cities)

Local Institution

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types